实用老年医学

实用老年医学 ›› 2010, Vol. 24 ›› Issue (1): 66-.

• 论著 • 上一篇    下一篇

老年晚期非小细胞肺癌单药二线培美曲塞或多西他赛化疗的临床观察

  

  • 出版日期:2010-02-20 发布日期:2010-03-26

Clinical observation of the effects of  pemetrexed or docetaxel as secondline drug for  advanced nonsmall cell lung cancer in elderly patients

  • Online:2010-02-20 Published:2010-03-26

被引次数

58

摘要：

目的比较单药二线培美曲塞或多西他赛化疗治疗老年晚期非小细胞肺癌（NSCLC）患者的疗效和不良反应。方法老年复发晚期NSCLC患者共56例，26例单药培美曲塞化疗：培美曲塞500 mg/m2，第1天静脉滴注，每3～4周为1周期；30例单药多西他赛化疗：多西他赛35 mg/m2，第1，8，15天静脉滴注，每4周为1周期。结果培美曲塞组和多西他赛组有效率分别为2311%、200%，中位生存期分别为98月、81月，1年生存率分别为192%、200%。2组不良反应均可耐受，培美曲塞组未发生Ⅲ度和Ⅳ度血液学不良反应。结论老年晚期NSCLC患者可从单药二线培美曲塞或多西他赛化疗中获益；培美曲塞不良反应更轻微。

Abstract:

ＯｂｊｅｃｔｉｖｅTo observe the efficacy and toxic reaction of  pemetrexed or docetaxel as secondline drug for  advanced nonsmall cell lung cancer (NSCLC)in elderly patients.ＭｅｔｈｏｄｓFiftysix elderly patients with  relapse NSCLC were divided into two groups.In singleagent pemetrexed group，26 cases received pemetrexed at a dose of 500 mg/m2 on first day，and repeated every 3 to 4 weeks. In singleangent docetaxel group，30 cases were treated with docetaxel at a dose of 35 mg/m2 weekly for 4 weeks as a  cycle.ＲｅｓｕｌｔｓThe effective rate in pemetrexed group and docetaxel group was 192%and 167%respectively；the median survival time was 98 months and 81 months, respectively;1year survival rate was 192% and 200%, respectively.In two groups,  the toxicities were tolerable.There was no grade  Ⅲ or Ⅳ  hematological toxicity in pemetrexed group.ＣｏｎｃｌｕｓｉｏｎｓElderly patients with relapse NSCLC could benefit from singleagent pemetrexed or docetaxel as secondline treatment. Pemetrexed has a more tolerable toxicity than docetaxel.